Sci-Thurs AM: YIS-05: Accuracy of Patient-Specific Dosimetry for Clinical Use in Targeted Radionuclide Therapy

2009 ◽  
Vol 36 (9Part3) ◽  
pp. 4315-4316
Author(s):  
J Grimes ◽  
S Shcherbinin ◽  
A Celler ◽  
B Birkenfeld ◽  
MH Listewnik ◽  
...  
2014 ◽  
Vol 41 (6Part15) ◽  
pp. 282-282
Author(s):  
A Besemer ◽  
B Titz ◽  
J Grudzinski ◽  
J Weichert ◽  
L Hall ◽  
...  

2007 ◽  
Vol 95 (6) ◽  
Author(s):  
Frank Rösch

Endoradiotherapy (targeted radionuclide therapy) is a systemic approach, involving a radiolabeled targeting vector with a well characterized biochemical strategy to selectively deliver a cytotoxic level of radiation to a disease site on a cellular/molecular level. The group of radiolanthanides has been considered both for imaging and therapy over many years. Some radiolanthanides have been and are increasingly applied for therapeutic purposes.However, the clinical use of endoradiotherapeuticals containing radiolanthanides requires a complex and interdisciplinary approach. It involves, among other factors, the choice of the most suitable lanthanide radionuclide (in terms of nuclear decay parameters such as type and energy of the particles emitted, half-life, decay products


2017 ◽  
Vol 62 (15) ◽  
pp. 6008-6025 ◽  
Author(s):  
Abigail E Besemer ◽  
Benjamin Titz ◽  
Joseph J Grudzinski ◽  
Jamey P Weichert ◽  
John S Kuo ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5776
Author(s):  
Elisabeth von Guggenberg ◽  
Petra Kolenc ◽  
Christof Rottenburger ◽  
Renata Mikołajczak ◽  
Alicja Hubalewska-Dydejczyk

The cholecystokinin-2 receptor (CCK2R) has been a target of interest for molecular imaging and targeted radionuclide therapy for two decades. However, so far CCK2R targeted imaging and therapy has not been introduced in clinical practice. Within this review the recent radiopharmaceutical development of CCK2R targeting compounds and the ongoing clinical trials are presented. Currently, new gastrin derivatives as well as nonpeptidic substances are being developed to improve the properties for clinical use. A team of specialists from the field of radiopharmacy and nuclear medicine reviewed the available literature and summarized their own experiences in the development and clinical testing of CCK2R targeting radiopharmaceuticals. The recent clinical trials with novel radiolabeled minigastrin analogs demonstrate the potential for both applications, imaging as well as targeted radiotherapy, and reinforce the clinical applicability within a theranostic concept. The intense efforts in optimizing CCK2R targeting radiopharmaceuticals has led to new substances for clinical use, as shown in first imaging studies in patients with advanced medullary thyroid cancer. The first clinical results suggest that the wider clinical implication of CCK2R-targeted radiopharmaceuticals is reasonable.


2014 ◽  
Vol 17 (2) ◽  
pp. 284-294 ◽  
Author(s):  
Shih-ying Huang ◽  
Wesley E. Bolch ◽  
Choonsik Lee ◽  
Henry F. Van Brocklin ◽  
Miguel H. Pampaloni ◽  
...  

Author(s):  
Meshari Alnaaimi ◽  
Abdelmoneim Sulieman ◽  
Mohammed Alkhorayef ◽  
Hasan Salah ◽  
Musa Alduaij ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document